Next Article in Journal
Safety and Efficacy of Ibrutinib in a Patient with Severe Renal Impairment
Previous Article in Journal
Single Step Multiple Genotyping by MALDI-TOF Mass Spectrometry, for Evaluation of Minor Histocompatibility Antigens in Patients Submitted to Allogeneic Stem Cell Transplantation from HLA-Matched Related and Unrelated Donor
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 9
Issue 3
10.4081/hr.2017.7028
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia

by
Michele Gottardi
1,*,
Federico Mosna
1,
Sergio de Angeli
2,
Cristina Papayannidis
3,
Anna Candoni
4,
Marino Clavio
5,
Cristina Tecchio
6,
Andrea Piccin
7,
Marta Campo dell’Orto
8,
Fabio Benedetti
6,
Giovanni Martinelli
3 and
Filippo Gherlinzoni
1
1
Hematology, Department of Specialty Medicine, General Hospital “Santa Maria di Ca’ Foncello”, Piazza Ospedale 1, 31100 Treviso, Italy
2
Laboratory of Cell Cryopreservation, General Hospital, 31100 Treviso, Italy
3
Department of Hematology, Institute “L.A. Seragnoli”, University of Bologna, 40127 Bologna, Italy
4
Department of Hematology, University of Udine, 33100 Udine, Italy
5
Department of Hematology, University of Genoa, 16145 Genoa, Italy
6
Department of Hematology, University of Verona, 37129 Verona, Italy
7
Department of Hematology, General Hospital, 39100 Bolzano, Italy
8
Department of Pathology, General Hospital, 31100 Treviso, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(3), 7028; https://doi.org/10.4081/hr.2017.7028
Submission received: 4 January 2017 / Revised: 23 April 2017 / Accepted: 27 April 2017 / Published: 26 September 2017

Abstract

Leukemia-initiating cells of core binding factor (CBF) acute myeloid leukemia (AML) likely derive from early committed hematopoietic precursors expressing CD33. As such, targeting CD33 could ameliorate the chance of cure of CBF AML patients. We compared 12 CBF AML patients treated with Fludarabine, Cytarabine, Idarubicin and Gemtuzumab Ozogamicin (FLAI-GO regimen) with 25 CBF AML patients treated with the same schedule, but without GO. With the limit of small numbers, we observed a consistent trend toward better overall survival, disease free survival and event free survival in the FLAI-GO group. We also demonstrated the ability of GO to induce the disappearance in vitro of the AML1-ETO molecular transcript in a polymerase chain reaction-positive graft without decreasing the clonogenic potential of CD34+/CD38- cells. This represent the proof of principle for using GO in a purging strategy before autologous stem cell transplantation. Therefore, our data argue in favor of the reinstitution of GO in the therapy of CBF AML.
Keywords: core binding factor; acute myeloid leukemia; gemtuzumab ozogamicin; immunotherapy; autologous stem cell transplantation core binding factor; acute myeloid leukemia; gemtuzumab ozogamicin; immunotherapy; autologous stem cell transplantation

Share and Cite

MDPI and ACS Style

Gottardi, M.; Mosna, F.; de Angeli, S.; Papayannidis, C.; Candoni, A.; Clavio, M.; Tecchio, C.; Piccin, A.; dell’Orto, M.C.; Benedetti, F.; et al. Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia. Hematol. Rep. 2017, 9, 7028. https://doi.org/10.4081/hr.2017.7028

AMA Style

Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, Tecchio C, Piccin A, dell’Orto MC, Benedetti F, et al. Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia. Hematology Reports. 2017; 9(3):7028. https://doi.org/10.4081/hr.2017.7028

Chicago/Turabian Style

Gottardi, Michele, Federico Mosna, Sergio de Angeli, Cristina Papayannidis, Anna Candoni, Marino Clavio, Cristina Tecchio, Andrea Piccin, Marta Campo dell’Orto, Fabio Benedetti, and et al. 2017. "Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia" Hematology Reports 9, no. 3: 7028. https://doi.org/10.4081/hr.2017.7028

APA Style

Gottardi, M., Mosna, F., de Angeli, S., Papayannidis, C., Candoni, A., Clavio, M., Tecchio, C., Piccin, A., dell’Orto, M. C., Benedetti, F., Martinelli, G., & Gherlinzoni, F. (2017). Clinical and Experimental Efficacy of Gemtuzumab Ozogamicin in Core Binding Factor Acute Myeloid Leukemia. Hematology Reports, 9(3), 7028. https://doi.org/10.4081/hr.2017.7028

Article Metrics

Back to TopTop